Abstract: Objective To analyze the adverse drug reactions(ADR) of the standardized treatment of multidrug-resistant tuberculosis(MDR-TB)，and to evaluate the impact on treatment. Methods  We designed the questionnaire of MDR-TB ADR through expert consultation, and retrospectively investigated MDR-TB patients’ medical records with standardized ADR questionnaire in He’nan Puyang city, Heilongjiang Daqing city, Zhejiang Quzhou city and Tianjin municipality. A total of 91 MDR-TB patients confirmed during March 1, 2010 to February 29, 2012 were enrolled in the analysis.  Results 89.0%(81/91) of 91 MDR-TB patients had adverse reactions(ADR). The most common ADR was gastrointestinal reaction which accounted for 35.4%(52/147), followed with hepatotoxicity，which accounted for 17.7%(26/147). After the ADR treatment, 55.1%(81/147) of patients maintained the original treatment regimen, 32.7%(48/147) patients changed or stopped ADR-induced drugs，only 7.5%(11/147) cases stopped MDR-TB treatment for ADR. The highest percentage of changed or stopped drug is amino acid (PAS), which accounted for 37.5%(18/48), the least percentage is kanamycin injections (Km), which accounted for 6.3%(3/48).  Conclusion ADR is common during the treatment course of MDR-TB, but the vast majority of ADR do not need to be dealt with. Attention should be paid to monitoring and management of ADR, drugs should not be stopped easily or even stopping treatment.

Key words: Tuberculosis, pulmonary/drug therapy, Drug resistance, multiple, bacterial, Drug-related adverse reactions, Treatment outcome